Summary
- Profile Type
- Technology offer
- POD Reference
- TOGB20250617010
- Term of Validity
- 17 June 2025 - 17 June 2026
- Company's Country
- United Kingdom
- Type of partnership
- Commercial agreement with technical assistance
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- UK med-tech company has developed a digital biomarker technology to improve the diagnosis and management of epilepsy. It analyses routine electroencephalogram (EEG) data to support diagnosis, even in the absence of visible seizures. Already in clinical use, it is now being adapted for prognostic care and interactions with other conditions such as traumatic brain injury. Seeking partners under commercial agreements with technical assistance.
- Full Description
-
A UK award-winning, med-tech company, spun out of the University of Exeter in 2018, has developed a digital health innovation to improve the diagnosis and monitoring of neurological conditions, with an initial focus on epilepsy. The core technology, BioEP is a digital biomarker that examines routinely recorded EEG data to identify characteristics linked to epilepsy. Unlike traditional methods that rely on the visual identification of seizures, this solution assesses background brain activity to support more confident and timely diagnostic decisions, even when no epileptiform activity is present.
Regulatory approval has been secured in the UK, with additional certifications in progress to support international expansion.
To maximise its global impact, the company are seeking partnerships across the healthcare ecosystem, in the fields of healthcare, medical devices, pharma and neurophysiology. They are particularly interested in:
Healthcare providers interested in integrating BioEP into clinical workflows, offering an innovative tool to enhance diagnostic processes for epilepsy.
Medical device manufacturers that produce EEG hardware or other neurodiagnostic devices and are interested in collaborating to integrate BioEP with their equipment for enhanced functionality.
Pharma companies interested in using BioEP as a tool to monitor the effects of neurological treatments, including anti-epileptic drugs, to assess treatment efficacy and tailor therapies to individual patients.
Academic and clinical research centres, as well as neurophysiology and neurology companies, looking to explore how innovative digital biomarkers and advancements in EEG analysis can enhance research and improve the standard of care.
Collaboration is sought under commercial agreements with technical assistance. Partnerships will help enhance and adapt this technology for wider use in clinical settings and support its evolution for broader applications in neurological health. - Advantages and Innovations
-
Unlike conventional methods that detect seizures after they occur, this technology identifies brain activity associated with epilepsy before symptoms emerge.
It delivers objective analysis to compliment clinical interpretation, making EEG analysis more robust and reliable.
The system is UKCA-certified, ISO13485-compliant and undergoing clinical validation for international expansion.
It is designed to integrate seamlessly with existing EEG workflows, minimising disruption to clinical routines.
Early-stage studies indicate it may also assist in evaluating treatment response, aiding both clinicians and pharmaceutical companies in drug discovery and repurposing. - Technical Specification or Expertise Sought
-
We are seeking expertise in:
Healthcare system integration
EEG device integration
Research, regulatory & clinical validation - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 9: Industry, Innovation and Infrastructure
- Goal 3: Good Health and Well-being
- IPR status
- IPR granted
- IPR notes
- IP information available on request
Partner Sought
- Expected Role of a Partner
-
Healthcare providers (private hospitals, global hospital systems) – To integrate the technology into clinical practice for enhanced epilepsy diagnosis.
Medical device & pharmaceutical companies – To explore its role in treatment monitoring and drug discovery.
EEG hardware manufacturers & service providers – To collaborate on seamless integration and data acquisition.
Role of partners:
Adopt and implement the technology in clinical workflows to improve epilepsy diagnosis.
Support regulatory validation efforts for FDA approval and CE certification.
Collaborate on R&D projects for expanding BioEP’s applications beyond epilepsy, including neurology and neurodegenerative diseases - Type and Size of Partner
- SME 11-49
- Big company
- SME <=10
- SME 50 - 249
- University
- Other
- R&D Institution
- Type of partnership
- Commercial agreement with technical assistance
Dissemination
- Technology keywords
- 06005004 - Remote diagnostics
- 06001005 - Diagnostics, Diagnosis
- Market keywords
- 05007006 - Computer-aided diagnosis and therapy
- Sector Groups Involved
- Digital
- Health
- Targeted countries
- All countries